Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form

Genetic deficiency in pparg does not alter development of experimental prostate cancer

Academic Article
uri icon
  • Overview
  • Identity
  • Additional Document Info
  • View All
scroll to property group menus

Overview

authors

  • Saez, Enrique
  • Olson, P.
  • Evans, R. M.

publication date

  • October 2003

journal

  • Nature Medicine  Journal

abstract

  • The role of the nuclear peroxisome proliferator-activated receptor (PPAR)-gamma in cancer has been a subject of debate. The identification of loss-of-function mutations in PPARG in colon and prostate tumors has led to the idea that this gene may function as a tumor suppressor. We have directly tested this notion using a mouse model of prostate cancer. Neither hemizygous deletion of Pparg nor complete ablation of Ppara influenced the development of prostate cancer in our experimental context.

subject areas

  • Animals
  • Disease Models, Animal
  • Humans
  • Male
  • Mice
  • Neoplasms, Experimental
  • Prostatic Neoplasms
  • Receptors, Cytoplasmic and Nuclear
  • Transcription Factors
  • Transgenes
scroll to property group menus

Identity

International Standard Serial Number (ISSN)

  • 1078-8956

Digital Object Identifier (DOI)

  • 10.1038/nm928

PubMed ID

  • 12960963
scroll to property group menus

Additional Document Info

start page

  • 1265

end page

  • 1266

volume

  • 9

issue

  • 10

©2021 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support